Hepatitis B, hepatitis C, and mortality among HIV-positive individuals

Objectives: To compare rates of all-cause, liver-related, and AIDS-related mortality among individuals who are HIV-monoinfected with those coinfected with HIV and hepatitis B (HBV) and/or hepatitis C (HCV) viruses. Design: An ongoing observational cohort study collating routinely collected clinical data on HIV-positive individuals attending for care at HIV treatment centres throughout the United Kingdom. Methods: Individuals were included if they had been seen for care from 2004 onwards and had tested for HBV and HCV. Crude mortality rates (all cause, liver related, and AIDS related) were calculated among HIV-monoinfected individuals and those coinfected with HIV, HBV, and/or HCV. Poisson regression was used to adjust for confounding factors, identify independent predictors of mortality, and estimate the impact of hepatitis coinfection on mortality in this cohort. Results: Among 25 486 HIV-positive individuals, with a median follow-up 4.5 years, HBV coinfection was significantly associated with increased all-cause and liver-related mortality in multivariable analyses: adjusted rate ratios (ARR) [95% confidence intervals (95% CI)] were 1.60 (1.28–2.00) and 10.42 (5.78–18.80), respectively. HCV coinfection was significantly associated with increased all-cause (ARR 1.43, 95% CI 1.15–1.76) and liver-related mortality (ARR 6.20, 95% CI 3.31–11.60). Neither HBV nor HCV coinfection were associated with increased AIDS-related mortality: ARRs (95% CI) 1.07 (0.63–1.83) and 0.40 (0.20–0.81), respectively. Conclusion: The increased rate of all-cause and liver-related mortality among hepatitis-coinfected individuals in this HIV-positive cohort highlights the need for primary prevention and access to effective hepatitis treatment for HIV-positive individuals.

[1]  V. Soriano,et al.  Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Sterne,et al.  The Coding Causes of Death in HIV (CoDe) Project: Initial Results and Evaluation of Methodology , 2011, Epidemiology.

[3]  H. Sørensen,et al.  Comorbidity Acquired Before HIV Diagnosis and Mortality in Persons Infected and Uninfected With HIV: A Danish Population-Based Cohort Study , 2011, Journal of acquired immune deficiency syndromes.

[4]  Joseph Eliahoo,et al.  Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men , 2010, Gut.

[5]  M. Mosunjac,et al.  Development of fatal acute liver failure in HIV-HBV coinfected patients. , 2010, World journal of gastroenterology.

[6]  Coris,et al.  Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study , 2010 .

[7]  M. Fischer,et al.  Hepatitis C and the Risk of Kidney Disease and Mortality in Veterans With HIV , 2010, Journal of acquired immune deficiency syndromes.

[8]  B. Agan,et al.  The Effect of Human Immunodeficiency Virus on Hepatitis B Virus Serologic Status in Co-Infected Adults , 2010, PloS one.

[9]  E. Ding,et al.  Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  B. Gazzard,et al.  The prevalence of hepatitis C virus (HCV) infection in HIV‐positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes , 2009, Journal of viral hepatitis.

[11]  J. Phair,et al.  Hepatitis B and long-term HIV outcomes in coinfected HAART recipients , 2009, AIDS.

[12]  A. Hatzakis,et al.  Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  P. Morlat,et al.  Liver‐related deaths in HIV‐infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19) * , 2009, HIV medicine.

[14]  Kholoud Porter,et al.  Survival following HIV infection of a cohort followed up from seroconversion in the UK , 2008, AIDS.

[15]  M. Kitahata,et al.  Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. , 2007, AIDS patient care and STDs.

[16]  Y. Benhamou.  Hepatitis B in the HIV-Coinfected Patient , 2007, Journal of acquired immune deficiency syndromes.

[17]  J. Guest,et al.  Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease , 2007, HIV medicine.

[18]  John T Brooks,et al.  Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.

[19]  O. Kirk,et al.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. , 2006, Archives of internal medicine.

[20]  J. Stephenson,et al.  Behavioural predictors of subsequent hepatitis C diagnosis in a UK clinic sample of HIV positive men who have sex with men , 2006, Sexually Transmitted Infections.

[21]  H. Sørensen,et al.  Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  P. Sullivan,et al.  Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy , 2006, AIDS.

[23]  A. Mayor,et al.  Morbidity and mortality profile of human immunodeficiency virus-infected patients with and without hepatitis C co-infection. , 2006, The American journal of tropical medicine and hygiene.

[24]  Mark R Wallace,et al.  Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras , 2006, Journal of acquired immune deficiency syndromes.

[25]  A. Mocroft,et al.  Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? , 2005, AIDS.

[26]  M. B. de Azevedo Barros,et al.  Characteristics and survival of AIDS patients with hepatitis C: the Brazilian National Cohort of 1995–1996 , 2005, AIDS.

[27]  A. Mocroft,et al.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.

[28]  Derek B Boothroyd,et al.  Effects of Hepatitis C Virus Coinfection on Survival in Veterans With HIV Treated With Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.

[29]  B. Yip,et al.  Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients , 2005, Canadian Medical Association Journal.

[30]  A. Mocroft,et al.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort , 2005, AIDS.

[31]  N. Voirin,et al.  Survival in HIV‐infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database , 2004, Journal of viral hepatitis.

[32]  A. Wohl,et al.  Survival in patients with HIV infection and viral hepatitis B or C: a cohort study , 2004, AIDS.

[33]  Kholoud Porter,et al.  The creation of a large UK‐based multicentre cohort of HIV‐infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study , 2004, HIV medicine.

[34]  Kholoud Porter,et al.  Determinants of survival following HIV-1 seroconversion after the introduction of HAART , 2003, The Lancet.

[35]  A. Moorman,et al.  Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  A. Mocroft,et al.  Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study , 2002, AIDS.

[37]  COST-EFFECTIVENESS IMPLICATIONS OF THE TIMING OF ANTIRETROVIRAL THERAPY IN HIV-INFECTED ADULTS , 2002 .

[38]  Richard D Moore,et al.  Hepatitis C and progression of HIV disease. , 2002, JAMA.

[39]  T. Heeren,et al.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  M. Loriot,et al.  Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men , 1999, Hepatology.

[41]  Qilong Yi,et al.  Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis , 2008, AIDS.

[42]  J. Bartlett.  The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy , 2004 .